ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

ASCO 2016 Gynecologic Cancers

ASCO 2016 Gynecologic Cancers

Researchers were able to molecularly classify endometrial cancers with distinct survival differences using a new classification tool called ProMisE that uses clinically applicable methods.

A concurrent chemotherapy and radiotherapy regimen with cisplatin and paclitaxel yielded a good response rate and strong long-term survival outcomes in patients with locally advanced or recurrent cervical cancer.

In this video Dr. Odunsi discusses a new study that found that higher T-cell diversity in ovarian cancer is associated with poor overall survival.

A live attenuated bioengineered bacteria-vectored vaccine immunotherapy is well tolerated and appears to be associated with promising overall survival among women with persistent/recurrent metastatic cervical cancer.

Despite hematologic toxicities and port-related adverse events, IP carboplatin plus IV dose-dense paclitaxel appears to be effective in patients with suboptimally debulked epithelial ovarian or primary peritoneal carcinoma.

Baseline quality of life measures predict early cessation of chemotherapy and overall survival in women with platinum-resistant/refractory, recurrent ovarian cancer.

Extending platinum-free interval with pegylated liposomal doxorubicin, topotecan, or gemcitabine does not improve overall survival among patients with recurrent ovarian cancer.

Pages

Subscribe to ASCO 2016 Gynecologic Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.